NovoCure Ltd — Director's Dealing 2019

Aug 1, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-07-24

Reporting Person: Benaim Ely (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Restricted Share Units	12616	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Buy Ordinary Shares	$47.56	2029-05-07	Ordinary Shares (23072)		Direct

Footnotes

F1: One-third of these restricted stock units are scheduled to vest on each of May 8, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.

F2: Options to buy 23,072 ordinary shares will vest and become exercisable in equal installments on each of May 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.